Oral contraceptives (OCs) are implicated in the development of hepatocellular carcinoma (HCC). Mitogenic stimulation may be the primary mechanism of tumorigenesLs, but other factors may also contribute. Mutational spectrum analysis can provide insights into pathogenesis, therefore we analyzed the p53 tumor suppressor gene in 10 HCCs from women with a history of OC use. All were non-Asians whose average OC use was 6.7 years (range 2 months-13 years) and whose mean age at HCC diagnosis was 48.8 years (range 21-67 years). Each tumor was analyzed by immunohistochemistry, DNA sequencing and allelic deletion analysis. Three tumors were positive by p53 immunohistochemistry; allelic deletion analysis identified loss of heterozygosity in one of four informative cases. Two p53 point mutations were found in one tumor containing moderately and well-differentiated components; this patient was negative for all serological markers of hepatitis B and C infections. Both components showed p53 protein accumulation and a GTT val ->GCT ala mutation at codon 274. In addition, a silent mutation (ACC thr ->ACT thr ) at codon 140 of the p53 gene was detected in the moderately differentiated component of the tumor. These preliminary data indicate that p53 mutations are uncommon in OCrelated HCCs. One of the two detected mutations was a G:C->A:T transition at a non-CpG site, which is characteristic of DNA damage by free radicals. These data support a model whereby estrogens contribute to HCC development primarily through mitogen stimulation and secondarily by mutagenesis via hydroxyl radicals produced during estrogen metabolism. Confirmational analysis of a larger series is warranted.
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Women with prolonged oral contraceptive (OC*) use have an increased risk of benign and malignant liver tumors, including focal nodular hyperplasia (1), adenoma (2,3) and carcinoma (HCC) (4) (5) (6) . OCs are combinations of estrogens and progestagens (7) which produce contraception primarily by inhibiting ovulation. Synthetic estrogens commonly used in OCs, such as ethinyl estradiol and mestranol (8) , can produce malignant liver tumors in rodents (9), probably by acting as promoting agents (10) (11) (12) . Furthermore, progestagens (norethisterone and norethynodrel), mainly of the first and second generation OCs, can cause benign liver neoplasia in animals (reviewed in 9).
•Abbreviations: OC, oral contraceptive; AFB1, aflotoxin Bl; HBV, hepatitis B virus.
Estrogens and progestagens are thought to cause liver cancer by mitogenesis; i.e. increased proliferation rates, which increase the rate of spontaneous mutations due to DNA polymerase errors (13) (14) (15) . Additional risk factors include hepatitis B and C infections, cirrhosis, dietary aflatoxin Bl (AFB1) exposure, cigarette smoking and heavy alcohol drinking (reviewed in 16). To investigate the role of OCs in human HCC development we examined the p53 tumor suppressor gene in HCCs from 11 non-Asian women with histories of OC use. We hypothesized that the frequency and pattern of mutations would provide clues to the mechanisms by which OCs cause HCCs.
p53 mutations are common in human cancers and mutational spectrum analysis has produced genetic evidence linking environmental agents to human cancers (reviewed in 17,18). For example, HCCs from regions with high dietary AFB1 exposure and endemic hepatitis B virus (HBV) infection contain a remarkable mutational hotspot in the third base position of codon 249, AGG^-^AGF" (17, 19, 20) . The p53 mutational spectrum in smoking-related lung cancers is dominated by G:C->T:A transversions, which are attributed to polycyclic aromatic hydrocarbons such as benzo[a]pyrene (17, 21, 22) . Cancers from sun-exposed skin contain mutations at pyrimidine dimers, which are characteristic of ultraviolet light damage (23) . Occupational exposure to vinyl chloride produces hepatic angiosarcomas containing predominantly A:T->T:A mutations, which are an uncommon mutation type in human cancers. This pattern has been seen in in vitro model systems (24) and is consistent with chemical activation of the vinyl chloride monomer. These are the current, best examples linking mutation profiles to specific etiological agents.
HCCs from 11 non-Asian (seven non-Hispanic white and four African-American) women of Los Angeles County with a history of OC use were collected. These were participants of a case-control study of HCC in which lifetime use of OC was asked as part of an in-person interview employing a structured questionnaire (4) . In this case-control study OC use was found to be a significant risk factor for HCC. The mean age of the 11 patients was 48.8 years (range 21-67 years). Table I lists the duration (mean 6.7 years, range 2 months-13 years) and brand names of OCs used by each study subject (4), as well as their history of tobacco and alcohol use and serum hepatitis B and C marker status. The formulations of the OCs used by the study subjects are shown in Table II .
Formalin-fixed tumor samples were microdissected from 50 urn thick paraffin sections as previously described (25) . Exons 5-8 were amplified in all patients and exons 4 and 9 were amplified for three tumor samples (patients 1, 3 and 8). Each exon was amplified by two sequential rounds of PCR using nested primers as reported (25) . Negative and positive controls were included in each set of reactions. PCR products were purified by electrophoresis on a 4% agarose gel (NuSieve 1:3) and sequenced by a modification of the dideoxy chain termination method of Sanger et al. (26) Alcohol history is described as current, ex-drinker or non-drinker. If the alcohol is history is current or ex-drinker then the average number of drinks/week is also listed. 'Sequence analysis included exons 5, 6, 7 and 8. Exons 4 and 9 were also analyzed in samples from patients 1, 3 directions. Two separate, independent PCR products were sequenced for each exon. Cases with mutations were examined for germline alterations at the same site using DNA from nonneoplastic tissues.
A polymorphism at codon 72 was analyzed by amplifying a region of exon 4 with two rounds of PCR (35 cycles each) using primers described by Weston et al. (27) . Purified PCR products were restricted by 20 U Bsh\ 2361 {Bacillus sphaericus RFL 1236) for 12 h at 37°C and analyzed on a 3% agarose gel. Using the primers of Weston et al. (27) Bsh 12361 identified two allelic fragments of 320 or 274 + 46 bp in the absence or presence of restriction site respectively. Each digestion reaction contained an internal control (27) . To detect a polymorphism in intron 3, which consists of a 16 bp insertion (28), the region was amplified by two rounds of PCR (35 cycles each) under the conditions described above using external primers 5'-CAGAGACCTGTGGGAAGCGA-3' and 5'-TGG-TGCAGGGGCCGCCGGTGTA-3' and nested primers 5'-ATGGGACTGACTTTCTGCTCTT-3' and 5'-CTGGCATTC-TGGGAGCTTCA-3'. PCR products were separated by electrophoresis on a 4% agarose gel (NuSieve 3:1).
Immunohistochemical analysis was performed using conventional peroxidase methods as previously reported (29) . Each experiment included positive and negative controls. The pattern of p53 immunostaining was assessed semi-quantitatively as follows: Neg, no nuclear staining present; 1 +, <10% of tumor nuclei stained; 2 + , 10-70% of tumor cell nuclei stained; 3 + , >70% of tumor nuclei stained.
Laboratory results and pertinent clinical information are shown in Table I . A histological review showed that the tumor from patient 3 contained two morphological components: welldifferentiated and moderately differentiated. Low (1+) or moderate (2+) nuclear accumulation of p53 protein was detected in tumor tissues from patients 1-3. Both the moderately and well-differentiated tumors from case 3 showed p53 staining, although the percentage of tumor nuclei stained was higher in the moderately differentiated than in the welldifferentiated component (2+ versus 1-2+ ).
Sequence analysis of exons 5-8 in tumor tissue from 10 patients identified one A:T-»G:C transition at codon 274 (exon 8) in both the moderately and well-differentiated components from patient 3. In addition, the moderately differentiated component contained a G:C-»A:T transition at codon 140 (exon 5). The transition at codon 274 (GTT val ->GCT ala ) was a missense mutation, while the transition at codon 140 (ACC lhr ->ACT thr ) was silent. In both mutations wild-type and mutant sequences were present, suggesting that one normal allele was retained (Figure 1) . Analysis of germline sequences from patient 3 indicated that both mutations were somatic alterations. Patient 3 had no evidence of hepatitis B and C infection; she was negative for serum hepatitis B surface antigen (HBsAg) and antibodies to HBsAg, hepatitis B core antigen (anti-HBc) and hepatitis C virus (anti-HCV). Non-tumor liver tissues from cases 1, 3, 8 and 10 were available for p53 allelic deletion analysis. All were tested for a polymorphism at codon 72 in exon 4 (30). Cases 1 and 10 were not informative (i.e. heterozygous) at this site, but they were informative for a polymorphism in intron 3 (28) . Analysis of corresponding tumor tissues identified p53 allelic loss only in the tumor from patient 8 ( Figure 2) .
Tumor tissues from patients 1 and 8 had p53 protein accumulation and p53 allelic deletion respectively. Sequence analysis of the commonly mutated regions in exons 5-8 showed only wild-type sequence. Because of the evidence for p53 alteration (i.e. immunohistochemistry and allelic deletion), the analysis was extended to include exons 4 and 9, but mutations were not found. This is the first report of p53 mutation analysis in human HCCs associated with OC use. Although OCs are linked to tumors of the liver, breast, endometrium and ovary (reviewed in 7), the mechanisms of tumorigenesis are unknown. The leading hypothesis is that OCs act as mitogens in some tissues to increase^cellular proliferation and the rate of spontaneous mutation through DNA polymerase errors (reviewed in 14, 15, 31 ). An alternative model is that estrogens increase the production of free radicals, which mediate direct genotoxicity (32) . In fact, synthetic estrogens, i.e. 17P-estradiol and diethylstilbestrol, are metabolized to cathecol estrogens, which may produce free radicals by metabolic redox cycling (32, 33) . In a hamster model both acute and chronic 17p"-estradiol administration produced oxidative damage to DNA in the liver and kidney (34) . The relatively low mutation rate in this series (10%) suggests that OCs did not cause direct DNA damage, but acted indirectly, possibly by mitogenesis. Alternatively, it has been suggested that OCs do not cause liver or breast cancers, but simply accelerate the growth of pre-existing tumors, either benign or malignant (35) .
In this series of 11 patients two mutations were found in one biphasic tumor. One of the two mutations was a G:C->A:T transition at a non-CpG site, which is characteristic of oxidative damage (36, 37) . It is notable that this patient had the longest interval of OC use (156 months). It is also significant that she had no evidence of hepatitis B or C infections, since inflammation due to hepatitis produces a variety of oxidative by-products (36, 38, 39) . The presence of the same missense mutation at codon 274 of the p53 gene in both the moderately and well-differentiated tumor components and a second, silent mutation at codon 140 only in the moderately differentiated component is a novel finding. It suggests that this biphasic tumor had a monoclonal origin and that loss of differentiation during tumor progression was linked to additional mutations in p53 and other genes. Alternatively, the second, silent mutation may reflect a high mutation rate within the developing neoplasm.
The frequency of p53 mutations depends on geographic origin. In areas of high AFB1 exposure and endemic HBV infection 54% of HCCs contain mutations in the p53 gene, while in HCCs from areas with low levels of AFB1 exposure the frequency of mutation is 28 and 29% in HBV-positive and HBV-negative cases respectively (reviewed in 17). In this series two p53 point mutations occurred in one tumor and another had allelic deletion; this indicates a mutation frequency of 20% (2/10). The immunochemistry results are consistent with this, since one case with a missense mutation was moderately positive and two cases were weakly positive. In general, high levels of protein correlate with missense mutation, while low levels occasionally signal mutation (40) (41) (42) (43) . In particular, the sporadic staining patterns observed in the tumors from patients 1 and 2 typically correlate with wild-type p53 function (40, 41) . Considering the low AFB1 exposure and moderate rate of hepatitis positivity (6/11 patients with evidence of B and/or C hepatitis), this mutation frequency of 20% is consistent with the current literature.
In conclusion, these data indicate a low p53 mutation frequency among OC-related HCCs. This supports a mitogenic model whereby OCs promote cell proliferation and generate tumors indirectly via endogenous mutagenic mechanisms. However, one of two mutations detected in this study is a G:C->A:T transition at a non-CpG site. Both features are characteristic of oxidative damage, which is consistent with a model whereby estrogen metabolism produces oxidative byproducts. This may indicate that oxidative damage contributes to the development of some estrogen-related tumors. These data provide a baseline for comparison with other tumors linked to hormone replacement therapy and chemopreventive agents such as tamoxifen. These data illustrate the potential of mutational spectrum analysis to generate hypotheses about cancer etiology. Analysis of a larger tumor series is warranted to confirm the findings of this initial study.
